Abstract Lines

Our Pipeline

Targeting fundemental biology for radical therapeutic benifits

Abstract Lines

Indication

Discovery

Preclinical

Phase I

Phase II

CB-18

Peptide mitophagy

activator

CB-1902

Small molecule

mitophagy activator

CB-1025

Acidifying

nanoparticles

Penetrating Keratoplasty
Macular degeneration
Muscular 
Dystrophy
Neuro-
Degeneration
Liver
Disease
Lysosomal
Diseases
Abstract Futuristic Background

Pipeline Fueled by Our MitoForm Platform

Unparalleled Scientific & Business Leadership